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Abstract
In 1H magnetic resonance spectroscopy, macromolecule sig-
nals underlaymetabolite signals, and knowing their contribution
is necessary for reliable metabolite quantiﬁcation. When mac-
romolecule signals are measured using an inversion-recovery
pulse sequence, special care needs to be taken to correctly
remove residual metabolite signals to obtain a pure macromol-
ecule spectrum. Furthermore, since a single spectrum is
commonly used for quantiﬁcation in multiple experiments, the
impact of potential macromolecule signal variability, because of
regional differences or pathologies, onmetabolite quantiﬁcation
has to be assessed. In this study, we introduced a novel method
to post-process measured macromolecule signals that offers a
ﬂexible and robust way of removing residual metabolite signals.
This method was applied to investigate regional differences in
the mouse brain macromolecule signals that may affect
metabolite quantiﬁcation when not taken into account. How-
ever, since no signiﬁcant differences in metabolite quantiﬁcation
were detected, it was concluded that a single macromolecule
spectrum can be generally used for the quantiﬁcation of healthy
mouse brain spectra. Alternatively, the study of a mouse model
of human glioma showed several alterations of the macromol-
ecule spectrum, including, but not limited to, increased mobile
lipid signals, which had to be taken into account to avoid
signiﬁcant metabolite quantiﬁcation errors.
Keywords: 1H magnetic resonance spectroscopy, glioma,
macromolecule.
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Over the last decade, proton magnetic resonance spectros-
copy (1H MRS) research has beneﬁtted from the develop-
ment of ultrahigh ﬁeld strength magnets, which allowed the
quantiﬁcation of an increased amount of up to 20 brain
metabolites, which constitute the neurochemical proﬁle
(Pfeuffer et al. 1999; Mlynarik et al. 2008). In addition to
brain metabolites, macromolecule (MM) resonances, which
are mainly ascribed to cytosolic proteins and mobile lipids in
certain pathological conditions (Kauppinen et al. 1992,
1993; Behar and Ogino 1993; Howe et al. 2003; Seeger
et al. 2003; Opstad et al. 2010), are also detected using 1H
MRS and consist of broad resonances that overlap with the
metabolite signals. However, the short relaxation times of
MM protons allow their signals to be discriminated from
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those of metabolites, which have longer relaxation times and
narrower linewidths. At low magnetic ﬁeld strengths, such as
1.5 T and 3 T, the broad MM signals have thus been
successfully estimated using mathematical functions such as
splines or wavelets (Soher et al. 2001; Schaller et al. 2013).
At increasing magnetic ﬁeld strengths, however, more MM
resonances can be distinguished (Otazo et al. 2006) and the
increasing metabolite linewidth complicates a clear differen-
tiation between the MM and J-coupled metabolite signals as
it has been shown using the inversion-recovery (IR)
technique and diffusion-weighted MRS at 14.1 T (Cudalbu
et al. 2009b; Kunz et al. 2010). It has also been shown that
an inadequate MM estimation at higher magnetic ﬁeld
strengths, using splines or truncation of the ﬁrst points of the
FID, for instance, may compromise a reliable metabolite
quantiﬁcation (Cudalbu et al. 2007, 2009b; Gottschalk et al.
2008; Mlynarik et al. 2008; Hong and Pohmann 2013).
Consequently, new strategies have been developed to
estimate MM signals at ultrahigh magnetic ﬁeld strength,
including measurement of MM signals (Pfeuffer et al. 1999;
Mlynarik et al. 2008; Cudalbu et al. 2009b) or simulation of
the MM components based on parameterization of prior
knowledge obtained from measured MM signals (Seeger
et al. 2003; Hong et al. 2011). Although measured MM
signals have been widely used in brain metabolite quantiﬁ-
cation in previous studies (Pfeuffer et al. 1999; Mlynarik
et al. 2008), attention has to be paid to the fact that regional
differences or pathological conditions may affect the MM
signals.
Previous studies have shown regional differences in
metabolite levels in the brain of animals and humans (Tkac
et al. 2003; Lei et al. 2010; Xin et al. 2010b), although only
few studies have focused on regional differences at the MM
level. A previous study in rats has shown no signiﬁcant
differences in the MM signals in several regions of the brain
(Xin et al. 2010a). Studies conducted in humans have found
slight differences in MM contribution in different brain
locations, possibly because of differences in white/gray
matter content (Mader et al. 2002). However, a study
performed at 7 T recently showed that MM differences
observed between gray and white matter did not signiﬁcantly
affect the 1H MRS metabolite quantiﬁcation (Schaller et al.
2012). Since a thorough investigation of MM variability has
not yet been performed in the mouse brain, although the
mouse brain is histologically more homogeneous with much
smaller white matter content than the human brain, it is still
unclear if potential regional differences, independently of
gray/white matter content differences, in MM contribution
may signiﬁcantly affect 1H MRS metabolite quantiﬁcation in
the mouse brain. This knowledge is especially important
when a single brain MM spectrum is used for the investi-
gation of several brain regions because of the signiﬁcant
amount of time that the measurement of the MM contribution
can require.
While many pathological conditions are associated with
metabolite level alterations, only a few of them, including
multiple sclerosis, stroke, and brain tumors, have so far been
investigated and linked to MM signal changes, which have
been ascribed to increases of mobile lipids (Graham et al.
2001; Mader et al. 2001; Howe et al. 2003; Seeger et al.
2003; Opstad et al. 2010). The increase in mobile lipid
signals observed in high-grade brain tumors has been linked
with malignancy (Murphy et al. 2003; Fan et al. 2004) and
has been associated with the extent of necrosis (Kuesel et al.
1994). An increase in mobile lipids has also been shown to
correlate with cell death and apoptosis (Hakumaki et al.
1999). However, while several studies of high-grade gliomas
in humans and animal models have reported increases in
mobile lipids in the affected tissue (Howe et al. 2003; Opstad
et al. 2010), acquisition of metabolite-nulled spectra was
rarely performed and only at low magnetic ﬁeld strength
(Seeger et al. 2003). None of these studies, therefore, was
able to report potential MM changes in the spectral region
where visual separation of MM from the metabolite signals is
not possible. An accurate measurement of the MM contri-
bution at high magnetic ﬁeld strength may, therefore, provide
such information.
One drawback of measuring MM signals is the amount of
time needed for establishing their contribution when inves-
tigating small regions of interest such as the mouse brain,
especially when each subject is expected to express different
MM alterations. Although this limiting factor is reduced
when investigating bigger brain structures such as the human
brain, a faster alternative to the MM measurement in each
subject is offered by the possibility of simulating MM signals
based on their parameterization (Seeger et al. 2003; Hong
et al. 2011). However, even in that case, a preliminary
precise measurement of the MM signals is still necessary for
correct assessment of the prior knowledge necessary for their
parameterization in given physiological or pathological
conditions.
The measurement of MM signals has traditionally been
performed using an IR sequence (Pfeuffer et al. 1999;
Mlynarik et al. 2008; Cudalbu et al. 2009b) with an
inversion time (TI) that allows an almost complete nulling
of the metabolite signals, while the MM signals, which have
shorter longitudinal relaxation times than metabolites, have
almost completely recovered. However, because of the
different longitudinal relaxation times of the metabolites
(de Graaf et al. 2006; Cudalbu et al. 2009a), their complete
nulling is typically difﬁcult to achieve. Hence, an accurate
in vivo determination of MM depends on the effective
removal of the residual metabolite signals. Until now, this
step has been performed using HLSVD (Hankel-Lanczos
Singular Value Decomposition) (Pijnappel et al. 1992),
which allows the selective removal of frequency components
but does not offer any ﬂexibility when these components
overlap with MM signals of similar linewidth.
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The primary aim of this study was, therefore, to establish
an improved in vivo measurement of the MM component by
implementing a method that can provide an accurate
separation and removal of metabolite residuals from the
MM components using prior knowledge of their frequency
and linewidth, even in the case of similar linewidths.
A secondary aim was to use this new method to measure
MM signals in different regions of healthy mouse brains to
detect potential regional differences that may affect metab-
olite quantiﬁcation if not taken into account. Finally, a third
aim was to study a mouse model of glioma derived from
human glioma-initiating cells (GIC) to detect whether MM
alterations may be induced by this pathology and thus should
be taken into account for accurate metabolite quantiﬁcation.
Material and methods
Female adult NOD-scid mice (Charles River Laboratories Inc.,
L’Arbresle, France), 6 weeks old, were housed in a 12 h light/dark
cycle, with ad libitum access to food and water. Protocols were
conform to Swiss legislation and the European Community Council
directive (86/609/EEC) for the care and use of laboratory animals
and conducted in compliance with ARRIVE (Animal Research:
Reporting In Vivo Experiments) guidelines. All animal studies were
approved by the local animal ethics committee.
Glioma-initiating cell mouse model
Unsorted tumor cells were obtained from human glioblastomas in
stage IV. Cells were cultured as ﬂoating colonies (gliomaspheres) in
Dulbecco’s modiﬁed Eagle’s Medium/F12 containing B27 (1/50),
epidermal growth factor and basic ﬁbroblast growth factor
(10 ng/mL). Prior to implantation into NOD-scid immunodeﬁcient
mice, the number of viable cells was determined by counting cells
using trypan blue exclusion. Seven NOD-scid mice injected in the
striatum with human GIC (number of passages > 11, number of
cells 7 9 104), referred to as CGIC, were scanned every 2 weeks
after the injection until tumor formation.
In vivo 1H MRS protocol
All experiments were carried out on an animal 26-cm-diameter,
horizontal-bore 14.1-T magnet (Magnex Scientiﬁc, Oxford, UK)
interfaced to a Direct Drive console (Varian Inc., Palo Alto, CA,
USA). The magnet was equipped with a 12-cm-inner-diameter
gradient (400 mT/m in 120 ls; Magnex Scientiﬁc). A custom-made
quadrature surface coil, consisting of two geometrically decoupled
14-mm diameter single loops, was used as a transceiver.
The mice were anesthetized with 3% isoﬂurane combined with a
mixture of air and O2, stereotaxically ﬁxed with two ear pieces and a
bite bar in a holder and placed at the isocenter of the magnet.
Throughout the experiment, the mice were kept anesthetized with
1.5–2% isoﬂurane. Breathing and temperature parameters were
monitored with an MR-compatible monitor system (model 1025; SA
Instruments, Stony Brook, NY, USA), and animal temperature was
maintained at 36.5–37.5°C by circulating warm water.
For localization of the volume of interest (VOI), multi-slice
T2-weighted imaging was performed using the fast spin echo technique
with a ﬁeld of view of 25 9 25 mm2, data matrix 2562, slice
thickness 0.8 mm, an effective echo time (TE) of 52 ms, and a
repetition time (TR) of 5000 ms.
Before the spectroscopy measurements, the static magnetic ﬁeld
homogeneity was adjusted using ﬁrst- and second-order shims with
an EPI version of FASTMAP (Gruetter and Tkac 2000).
In vivo macromolecule spectrum acquisition and post-processing
in the healthy mouse brain
The brain MM spectrum was acquired using SPECIAL (Mlynarik
et al. 2006) with a 2 ms full-passage hyperbolic secant adiabatic RF
inversion pulse applied before the localization sequence (Mlynarik
et al. 2008). The sequence was combined with a VAPOR water
suppression scheme interleaved with outer volume saturation
modules (Tkac et al. 1999). Differences in T1 relaxation were used
to discriminate residual metabolite signals from the MM spectrum in
series of IR acquisitions with TI varying from 600 to 900 ms using
shorter and longer echo time (TE = 2.8 and 40 ms) and a TR of
2.5 s. Series of IR acquisitions were also used to determine the best
TI to minimize the metabolite signals. An averaging of 1024
repetitions was acquired for each spectrum in a series of IR scans.
The MM signals were then acquired with a TI of 775 ms, a TE of
2.8 ms, a TR of 2.5 s and an averaging of 2048 repetitions.
The spectrum of pure MM was obtained after removal of the
residual metabolite signals in the metabolite-nulled spectra obtained
at TI = 775 ms. Residual metabolite peaks were removed using
AMARES (advanced method for accurate, robust, and efﬁcient
spectral ﬁtting) (Vanhamme et al. 1997), where constraints on peak
frequency, phase, linewidth, and amplitude were set to ﬁt the
residual peaks to be removed. The setting of the constraints was
based on prior knowledge of the frequency, phase and in vivo
linewidth of the residual metabolite peaks while allowing a small
degree of freedom to take experimental condition and physiological
effects into account. The MM spectrum devoid of any residual
metabolite signal corresponds to the ‘residue’ in AMARES (which
is obtained in AMARES after subtraction of the ﬁtted residual
peaks, the ‘estimate’ in AMARES, from the metabolite-nulled
spectrum). Manual iterative ﬁtting was then performed to improve
the accuracy of the estimate of the residual metabolite peaks at each
step by redeﬁning stronger constraints on the amplitude and
linewidth of the residual peaks to ﬁt. The previous residual peak
estimate and corresponding MM spectrum, if still considered not
completely devoid of metabolite contributions, were used to visually
determine which parameter should be reﬁned or modiﬁed for better
peak ﬁtting of the residual metabolite contribution. An accurate MM
spectrum was considered to be obtained when the metabolite
contribution to the MM spectrum was visually minimized. Since this
procedure had to be manually repeated for each measured MM
spectrum to post-process, a set of prior knowledge (on the number
of peaks, peak frequency, phase and relative linewidth between
peaks) associated with constraints, soft enough to be reused for each
new procedure (providing similar experimental conditions), was
carefully established to reduce the time needed for the procedure.
The use of such prior knowledge may furthermore provide a way to
limit any potential operator inﬂuence on the post-processing step.
For comparison with this newly proposed post-processing method,
the residual metabolite peaks were also removed with HLSVD
(Pijnappel et al. 1992).
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Assessment of post-processing and regional effects on the
macromolecule contribution
Brain MM spectra were obtained (using the post-processing
described above) in several regions of three healthy mice after
acquisition of metabolite-nulled spectra in the striatum (STR,
VOI = 8 lL), hippocampus (HIP, VOI = 6.75 lL) and in a region,
referred to here as mixed-tissue region, that included tissues of
several brain structures (MIX, VOI = 27 lL), partially including
striatum and hippocampus, using the same acquisition parameters as
describe above. Localized 1H MR spectra were acquired using the
SPECIAL sequence (TE = 2.8 ms; TR = 4000 ms, 512 repetition
scans) in the striatum and hippocampus of those mice.
In vivo 1H spectra were processed as previously described
(Mlynarik et al. 2008), frequency drift corrected, summed, and
eddy-current compensated using the water signal from the same
VOI. The experimental spectra were ﬁtted with LCModel (Proven-
cher 1993), using a simulated basis set of metabolites and MM
signals measured in vivo using an inversion-recovery sequence and
post-processed as described above. The metabolite basis set
included alanine (Ala), ascorbate (Asc), aspartate (Asp), creatine
(Cr), myo-inositol (myo-Ins), gamma-aminobutyric acid (GABA),
glucose (Glc), glutamine (Gln), glutamate (Glu), glycine (Gly),
glycerophosphocholine (GPC), glutathione (GSH), lactate (Lac),
N-acetyl-aspartate (NAA), N-acetyl-aspartyl-glutamate (NAAG),
phosphocholine (PCho), phosphocreatine (PCr), phosphorylethanol-
amine (PE), scyllo-inositol (Scyllo), and taurine (Tau).
Absolute quantiﬁcation of the 1H spectra was performed using the
water signal as an internal reference. The water spectra were
acquired with the same parameters, without water suppression and
with eight averaging scans.
In vivo macromolecule spectrum acquisition and metabolite
quantification in the glioma-initiating cell mouse model
Brain MM spectra were measured inside the tumor of seven mice
between 8 and 9 weeks post-injection of the CGIC. At this growth
stage, the tumor had a size that allowed the location of a VOI of
10–16 lL entirely within the tumor. Metabolite-nulled spectra were
acquired in the tumor VOI, which was located in a mixed-tissue
region that mostly included striatum and hippocampus tissues
(TI = 775 ms, TE = 2.8 ms, TR = 2.5 s, 2048 averages). 1H
metabolite spectra were also acquired in an 8 lL volume inside
the tumor (TE = 2.8 ms; TR = 4000 ms, 512 averages).
To detect potential alterations of the MM signals in the brain
tumor tissue compared to healthy brain tissue, metabolite spectra
acquired in the tumors were quantiﬁed using both the MM spectrum
of the tumor tissue, which was considered to be the closest to the
true MM spectrum, and a MM spectrum obtained in the same brain
region (mixed tissues) of a healthy mouse.
Statistical analyses
To detect differences in the MM spectra that signiﬁcantly affect
metabolite quantiﬁcation because of the used MM post-processing
methods, metabolite striatum spectra acquired in the healthy mice were
quantiﬁed using MM spectra obtained after AMARES and HLSVD
post-processing. The two types of quantiﬁcation were performed on
each mouse metabolite spectrum of the entire group before a paired
Student’s t-test was applied on the two types of quantiﬁcation to detect
signiﬁcant differences in the quantiﬁcation results.
To detect differences in MM signals between different brain
regions that might signiﬁcantly affect metabolite quantiﬁcation, the
same metabolite spectrum acquired in the striatum (or hippocampus)
was quantiﬁed with a MM spectrum obtained in the speciﬁc region
and in a bigger VOI that included several brain tissues (mixed-tissue
region). The two types of quantiﬁcation were performed on each
mouse spectrum in the entire group before a paired Student’s t-test
was applied on the two types of quantiﬁcation to detect signiﬁcant
differences.
In addition, to determine whether differences between MM
spectra of mice and rats signiﬁcantly affect metabolite quantiﬁca-
tion, a paired Student’s t-test was applied to the metabolite
quantiﬁcation results of each mouse in the entire healthy mouse
group obtained after using a mouse and a rat MM spectrum from a
mixed-tissue region.
Finally, to detect whether signiﬁcant alterations of the MM
signals in the tumor tissue affected metabolite quantiﬁcation, the two
types of quantiﬁcation, using the MM spectrum of the tumor tissue
and the MM spectrum obtained in a healthy mouse, were performed
over the entire group, and a paired Student’s t-test was applied to
determine the signiﬁcance of their differences.
Results
Optimization of the macromolecule spectrum acquisition
and post-processing in the healthy mouse brain
The optimal TI for measuring metabolite-nulled spectra was
determined to be 775 ms, as a result of the overall
minimization of the residual metabolite signals, although
the different T1 relaxation times of the metabolite resonances
prevented a complete nulling of all the metabolite signals.
The negative residual metabolite peaks in the IR series, as
well as the residual signals detected at long echo-time IR
acquisition, were used to identify the residual peaks that
needed to be removed from the metabolite-nulled spectra.
Residual metabolite removal with AMARES versus HLSVD
The new MM post-processing method proposed in this study
consisted of using AMARES to ﬁt the residual metabolite
peaks in the metabolite-nulled spectra before removing their
contribution from the measured spectrum to ﬁnally obtain an
accurate MM spectrum (Fig. 1a). The possibility of including
prior knowledge for the ﬁtting of residual metabolite peaks
associated with the manual iteration of the method for
reﬁning constraints on the frequency, amplitude, and
linewidth of the estimated metabolite residuals until an
optimized assessment of their estimation was obtained,
allowed for the reliable estimation and removal of all
residual metabolite peaks in all cases (Fig. 1b and c).
For comparison, a metabolite-nulled spectrum acquired in
the mixed-tissue region and processed with HLSVD is
shown in Fig. 2a. The lack of constraints on the amplitude
and linewidth of the estimated peaks in HLSVD led to clear
differences in the removal of several residual metabolite
peaks when compared with the AMARES method, as
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visually apparent at e.g., 3.91 ppm (Cr), 3.25 ppm (Tau) and
2.34 ppm (Glu).
Quantiﬁcation of the striatum metabolite spectra using the
MM signals processed using AMARES and HLSVD allowed
the reliable measurement of 15 metabolite concentrations
with Cramer-Rao lower bounds (CRLB) smaller than 10%
(Fig. 2b). However, although MM signals processed with
AMARES allowed a reliable quantiﬁcation of PCho and
GPC, this was not the case when using MM signals
processed with HLSVD. Only results for tCho are, therefore,
reported. In addition, Scyllo, NAAG, and Asp were quan-
tiﬁed, but their quantiﬁcation reliability was lower in general
(both when AMARES and HLSVD was used) and some data
had to be excluded (CRLB > 30%), leading to a too small
sample size that was not included in the statistical analysis.
The statistical analysis performed on the quantiﬁcations
obtained with the two differently processed MM spectra
highlighted several signiﬁcant quantiﬁcation differences in
GABA, Glu, Gly, Ins, Tau and tCho. Those metabolite
concentrations were found to be 20%, 7%, 29%, 13%, 13%
(p < 0.05) and 35% (p < 0.01) lower, respectively, when
using HLSVD for MM spectra post-processing.
The effect of regional macromolecule differences on
metabolite quantification
The MM spectra obtained from metabolite-nulled spectra
acquired in the hippocampus, striatum, and in a mixed-tissue
region showed no major visually detectable differences (Fig. 3a
and b). The statistical analysis of the measured metabolite
concentrations likewise showed no statistically signiﬁcant
differences when different MM spectra were used for the
metabolite quantiﬁcation of a given VOI (Fig. 3c and d).
The concentration differences were below 10% for most of
the metabolites in both striatum and hippocampus areas. Note
that in the hippocampus larger, although non-signiﬁcant,
differences were found for Asc, Gly and PE (15–40%). The
signal of these metabolites partially overlaps with the MM group
that resonates at 3.9 ppm and which has a slightly different
shape in the mixed-tissue region and in the hippocampus.
The additional quantiﬁcation of metabolite spectra
acquired in both hippocampus and striatum regions per-
formed using a general rat brain MM spectrum resulted in
similar metabolite concentrations compared to when using
the regional mouse brain MM spectra. In addition, the
statistical analysis between both metabolite quantiﬁcations
did not reveal any signiﬁcant difference in the metabolite
concentration measured when either the regional MM
spectrum or the general rat brain MM spectrum was used
(Fig. 3c and d).
In vivo MM spectrum acquisition in a glioma-initiating cell
mouse model and metabolite quantification
Based on a series of IR spectra, TI of 775 ms was determined
to be optimal for nulling metabolites within the brain tumor,
similar to the healthy mouse TI. Residual metabolite signals
were efﬁciently removed with AMARES as described above
for the healthy mouse. The MM spectra obtained from the
GIC mice showed visually clearly discernible differences
Estimate
Residue
13 24 ppm
Original
(a)
13 24 ppm
HIP
STR
MIX
(b)
13 24 ppm
HIP
STR
MIX
(c)
Before AMARES
After AMARES
Cr Cr NAA
TauGlx
Ins
Glx
NAA
Fig. 1 (a) Application of AMARES (advanced method for accurate,
robust, and efﬁcient spectral ﬁtting) for the proposed macromolecule
(MM) post-processing method. Residual metabolite peaks (dotted
lines) are selected in the acquired metabolite-nulled (original) spectrum
and ﬁtted using the available constraints on their frequency, phase,
linewidth, and amplitude. Once the optimal estimate of the residual
metabolite peaks is reached after several ﬁtting iterations with
constraint optimization, the AMARES residue corresponds to the MM
spectrum. (b) Metabolite-nulled spectra were acquired in the hippo-
campus (HIP), striatum (STR) and in a mixed-tissue region (MIX) of a
healthy mouse. The residual metabolites can be clearly observed. The
location of the volume of interest (VOI) is shown on the anatomical
images on the left. (c) The corresponding post-processed MM signals
no longer contain the residual metabolites.
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Fig. 2 (a) From bottom to top: a metabolite-nulled
spectrum acquired with TI = 775 ms in the mixed-
tissue region of a healthy mouse and the same
macromolecule (MM) spectrum post-processed
using either Hankel-Lanczos singular value
decomposition (HLSVD) or AMARES (advanced
method for accurate, robust, and efﬁcient spectral
ﬁtting), respectively. Dotted lines indicate the more
prominent differences in residual peaks removal
for creatine (Cr), taurine (Tau) and glutamate
(Glu). Note for example the removal of the
macromolecule peak next to creatine. (b)
Metabolite quantiﬁcation of the striatum (STR)
metabolite spectra (n = 3) using the MM spectra
obtained either after AMARES or HLSVD post-
processing. Signiﬁcant metabolite quantiﬁcation
differences between both methods are indicated
with *p < 0.05 and **p < 0.01. Error bars represent
the SD.
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Fig. 3 Spectra acquired in the hippocampus (HIP) (a) and in the
striatum (STR) (b) of a healthy mouse with the macromolecule (MM)
signals acquired in the same brain region (HIP or STR) or in a mixed-
tissue region (MIX). (c and d) Metabolite quantiﬁcation results (n = 3)
using either the MM signal from the same brain region, the mixed-
tissue region or from a rat mixed-tissue brain region. Metabolite levels
are displayed with error bars representing the SD of the measurement.
No visually apparent signiﬁcant differences can be observed in the MM
spectra, and similarly no statistically signiﬁcant differences were
observed in the quantiﬁed concentrations.
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from the MM obtained in healthy mice (Fig. 4). Additional
peaks, not present in healthy mouse MM spectra, were
detected at 1.3 and 2.8 ppm in the MM spectra of GIC mice.
Moreover, the GIC mouse spectra demonstrated an increase
in the MM component between 3.5 and 3.7 ppm compared to
healthy mouse MM spectra. An increased variability in the
MM spectrum was also observed in the GIC mice, which was
ascribed to brain MM modiﬁcations associated with the
glioma, of which the development stage was slightly
different in each mouse.
The quantiﬁcations of the tumor spectra performed using
the MM spectrum from a healthy brain mixed-tissue region
and from the investigated mouse tumor to detect whether
signiﬁcant quantiﬁcation bias was caused by neglecting to
take brain MM signals alterations that occur in tumorous
tissues into account showed several qualitative differences.
While all the metabolites included in the basis set except Glc
and GPC were reliably quantiﬁed (CRLB < 30%) when the
tumor MM spectrum was used, three metabolites, Ala, GSH,
and NAAG, failed to be quantiﬁed when the healthy tissue
MM spectrum was used. Moreover, all metabolites were
quantiﬁed with higher CRLB when the MM spectrum
acquired from healthy tissue was used. Furthermore, this
quantiﬁcation resulted in non-noise residuals and a distorted
baseline, including a consistently positive baseline distortion
between 3.6 and 3.7 ppm. This distortion corresponded to
the spectral region where an increase in MM signals of the
tumor tissue was observed. These residuals and distortion
were minimized when the MM spectrum from the tumor was
used. The statistical analysis performed on both quantiﬁca-
tions resulted in the detection of signiﬁcant differences in the
measured metabolite concentrations (Table 1). Asp was
signiﬁcantly underestimated with 23%, while Lac was
signiﬁcantly overestimated with 61% when the healthy tissue
MM spectrum was used (p < 0.003). Moreover, several
statistically non-signiﬁcant trends were detected such as an
overestimation of 11% of PCr (p < 0.09), 31% of PCho
(p < 0.06) and 29% of Glu (p < 0.09), as well as an
underestimation of 18% of the GABA level (p < 0.06).
Discussion
In this study, we presented a novel method for the post-
processing of the measured MM spectra to achieve an
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Fig. 4 (a) Metabolite spectrum acquired in the tumor region of a
glioma-initiating cell (GIC) mouse displayed with the volume of interest
(VOI) in the tumor indicated on a T2-weighted image (inset). Macro-
molecule (MM) signals of brain tumors in seven GIC mice are
displayed underneath (b–h). For comparison, three brain MM signals
acquired in the same brain region of healthy mice are also displayed
(i–k). The shaded areas indicate visual differences in the shape of the
MM signals between healthy and GIC mice at 3.6–3.7 ppm and
1.3 ppm. Differences were also observed at 2.8 ppm but only in some
of the GIC mice.
Table 1 Metabolite quantiﬁcation differences in the GIC mice (n = 7)
when a healthy mouse MM spectrum was used instead of the speciﬁc
MM spectrum acquired within the mouse tumor
Metabolite Quantiﬁcation difference [%] Concentration [lmol/g]
Asp 23  5* 1.10  0.40
PCho +31  35 0.88  0.24
Cr 9  20 2.94  1.13
PCr +11  14 2.45  0.25
GABA 18  8 0.66  0.17
Gln 7  17 2.51  1.02
Glu +29  39 4.11  0.77
Gly +39  64 2.53  1.83
Ins +5  16 9.24  2.98
Lac +61  31* 13.23  4.32
NAA +20  40 1.72  0.39
Scyllo 5  30 0.34  0.10
Tau 2  7 11.35  2.89
Asc 0  46 2.55  1.33
PE +13  27 2.53  0.69
tNAA 5  23 1.93  0.31
Glu+Gln +12  19 6.62  1.51
tCho +4  25 0.90  0.28
tCr +6  8 5.50  0.93
The average metabolite concentration difference obtained in seven
GIC mice is displayed with the SD of this difference. The signiﬁcance
of the difference of the metabolite quantiﬁcation is indicated by
*p < 0.003. In addition, metabolite concentrations measured in the
tumor of the GIC mouse model (n = 7) when the speciﬁc tumor MM
spectra were used for quantiﬁcation are also displayed.
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improved assessment of the MM spectrum through an
accurate separation and removal of the residual metabolite
peaks from the MM component. Potential regional and
pathological differences that might affect the MM spectrum
of the mouse brain and, therefore, the quantiﬁcation accuracy
were investigated.
The novel method proposed for the post-processing of
MM spectra based on AMARES was used for a robust
removal of the residual metabolite peaks from the MM
component. The high ﬂexibility of the AMARES method,
which allows the deﬁnition of constraints on the linewidth,
frequency, phase, and amplitude of the components used for
the ﬁtting of the metabolite residuals, appears to be more
successful than HLSVD in discriminating residual metabolite
signals from the MM components. Indeed, as can for
example be seen in Fig. 2a for the 3.9 ppm creatine peak,
HLSVD did not consistently succeed in separating metabo-
lite from MM resonances when the metabolite had a positive
phase and the MM component underneath had a relative
narrow linewidth. On the contrary, the possibility of putting
constraints on the linewidth and amplitude of the residual
metabolite peaks in AMARES consistently allowed the
robust separation of the residuals from the MM resonances,
even in the case of relative narrow MM resonance linewidth.
In other cases when small metabolite contributions were
difﬁcult to estimate, the IR series helped to establish the
reliability of the MM signal. However the IR series is not
always available because of time limitations and, in its
absence, metabolite residual contributions such as those of
Glu and Tau might be difﬁcult to estimate as a result of their
location on the MM resonance peaks. When HLSVD was
used, it was indeed difﬁcult to evaluate the correct MM
signal shape and if the metabolite residuals were correctly
estimated. The advantage of AMARES over HLSVD is that
by varying the ﬁt constraints, residual metabolite peaks could
be virtually over- or underestimated such that the best ﬁts of
the residual metabolite peaks were obtained when the
residual signal was exactly compensated. An imperfect
removal of these metabolite residuals with HLSVD was
furthermore suggested by the signiﬁcant differences detected
in the quantiﬁcation results when AMARES was used
instead of HLSVD for the MM post-processing.
The statistical analysis of the metabolite quantiﬁcation
using AMARES and HLSVD post-processed MM spectra
showed not only signiﬁcant quantiﬁcation differences in
metabolites that overlap with the MM components but also
for other metabolites such as Gly, which suggests that the
accuracy of the removal of residual metabolite signals in the
MM spectrum signiﬁcantly affects the quantiﬁcation of many
metabolites, especially those that have a weaker representa-
tion in the spectra. As such, the AMARES method, which
offers a greater ﬂexibility for the accurate ﬁtting of residual
metabolite peaks, appears to be the best alternative for
the post-processing of the MM components. An accurate
measurement of the MM spectrum is especially crucial for a
reliable metabolite level monitoring in speciﬁc cases when
the MM spectrum is altered and changes with disease
progression such as in stroke, multiple sclerosis, and tumors
(Graham et al. 2001; Mader et al. 2001; Howe et al. 2003;
Opstad et al. 2010).
The investigation of potential regional differences that
might affect the healthy mouse brain MM signals, similar to
what has been observed in the rat brain (Xin et al. 2010a),
showed that no difference between the MM signals of
different brain regions has a signiﬁcant impact on the
quantiﬁcation of the brain metabolites. Indeed, the MM
spectra were shown to be very similar throughout the
different brain regions and the few slight variations of the
MM signals observed between different brain regions were
shown to not signiﬁcantly affect metabolite quantiﬁcation.
Most of the metabolites were quantiﬁed with differences
lower than 10% when using the mixed-tissue instead of the
region-speciﬁc MM spectrum, which is within the typical SD
of the concentration measurement. Higher differences were
obtained only for a few low-concentration metabolites (Asc,
Gly, PE) that were quantiﬁed with lower precision, which
explains these higher differences in quantiﬁcation. These
results thus suggest that a unique MM spectrum acquired in a
fairly large region that contains mixed tissues of a healthy
mouse brain can be generally used for the brain metabolite
quantiﬁcation of any brain region in a healthy mouse. The
similar results obtained when comparing the quantiﬁcation
using either the mouse or the rat MM spectrum of similar
brain areas suggest that this can be generalized to the use of a
region-non-speciﬁc rat or mouse brain MM spectrum for
quantiﬁcation of metabolites in healthy animal brains of both
species.
Since brain pathologies may alter the MM and brain lipid
content (Graham et al. 2001; Mader et al. 2001; Howe et al.
2003; Seeger et al. 2003; Opstad et al. 2010), we studied a
mouse model of human brain glioma. In several mice of this
glioma-initiating-cell model, MM peaks that were not
detected in the brain of healthy mice were observed at
1.3 ppm and at 2.8 ppm. These signals correspond to mobile
lipid signals that have already been observed in previous
in vivo and in vitro studies on human and animal model brain
gliomas (Remy et al. 1997; Hakumaki et al. 1999; Auer
et al. 2001; Howe et al. 2003; Opstad et al. 2010). Those
signals, when not taken into accounts in the MM spectrum or
other basis sets, led to signiﬁcant errors in quantiﬁcation of
Lac and Asp, which overlap with the neglected lipid signals.
Although the presence of the mobile lipid peak at 1.3 ppm is
well known and has generally been taken into account in
quantiﬁcation in previous investigations of brain gliomas
using either simulated or parameterized lipid resonances
(Auer et al. 2001; Seeger et al. 2003; Opstad et al. 2010;
Doblas et al. 2012), the presence of lipids at 2.8 ppm has
been rarely included in the quantiﬁcation of in vivo spectra
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(Seeger et al. 2003; Opstad et al. 2010). However, our
results demonstrated the importance of taking its contribution
into account, especially when Asp quantiﬁcation is of
interest.
Moreover, a modiﬁcation in the MM spectrum was
detected in the spectral region at 3.6–3.7 ppm in the tumor
brain tissue, with the presence of a broad signal that was not
observed in any brain region studied in the healthy mouse.
This MM signal modiﬁcation has not been observed in
previous studies, as none of them measured the MM
spectrum at such high magnetic ﬁeld strength. Indeed,
unlike the lipid signals, the MM signals in brain gliomas
have been measured in only a few studies (Howe et al.
2003; Seeger et al. 2003) that were performed at low
magnetic ﬁeld strength and longer echo time, where the MM
contribution is minimized and poorly resolved. Both these
aspects contributed to an increased difﬁculty to detect small
or smooth changes in the MM signals at low magnetic ﬁeld
strength and/or longer echo time, where such slight changes
may have a lower impact on metabolite quantiﬁcation than at
higher magnetic ﬁeld strength. Moreover, the broad MM
resonance observed between 3.6 ppm and 3.7 ppm does not
correspond to any mobile lipid signal reported in previous
studies performed in vitro on glioma cells or in vivo on brain
gliomas (Hakumaki et al. 1999; Delikatny et al. 2011;
Mirbahai et al. 2012). This modiﬁcation might be a result of
structural changes of the MM components because of the
tumor. Further investigations are needed to be able to
explain the presence of this MM signal in glioma tissue,
which may be of interest for an improved characterization of
gliomas. However, the oversight of this additional MM
component in the MM spectrum did not lead to any
signiﬁcant error in the metabolite quantiﬁcation, since
LCModel was able to compensate for this neglected
contribution in the spectra in the quantiﬁcation baseline.
The resulting distorted baseline, however, may provide an
explanation for the generally lower reliability of the
metabolite quantiﬁcation (higher CRLB and fewer metabo-
lites successfully quantiﬁed) that was observed when a non-
complete MM spectrum was used.
We conclude that the novel MM post-processing method
based on AMARES presented in this study provides an
efﬁcient way to accurately separate and remove the residual
metabolite peaks from the measured MM component and
therefore provides an improved in vivo assessment of the
pure MM spectrum. We further conclude from the obtained
results using this optimized method that a unique non-
speciﬁc brain MM spectrum can be used for a general
quantiﬁcation of healthy mouse or rat brain metabolite
spectra. Finally, we conclude that an accurate assessment of
the modiﬁcations in the MM contribution in glioma spectra
that were seen not limited to lipid signals, is necessary for
reliable metabolite quantiﬁcation, while it might also provide
an additional characterization of the pathology.
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